[go: up one dir, main page]

GT200400098A - Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas. - Google Patents

Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas.

Info

Publication number
GT200400098A
GT200400098A GT200400098A GT200400098A GT200400098A GT 200400098 A GT200400098 A GT 200400098A GT 200400098 A GT200400098 A GT 200400098A GT 200400098 A GT200400098 A GT 200400098A GT 200400098 A GT200400098 A GT 200400098A
Authority
GT
Guatemala
Prior art keywords
aterosclerosis
dyslipidemias
treatment
pharmaceutical compositions
related conditions
Prior art date
Application number
GT200400098A
Other languages
English (en)
Inventor
Kang Cheng
Kathleen M Metters
Gary O'neill
M Gerard Waters
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200400098(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200400098A publication Critical patent/GT200400098A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO PARA TRATAR LA ATEROSCLEROSIS, EN EL QUE SE ADMINISTRA AL PACIENTE ACIDO NICOTINICO U OTRO AGONISTA DEL RECEPTOR DE ACIDO NICOTINICO EN COMBINACION CON UN ANTAGONISTA DEL RECEPTOR DP. EL ANTAGONISTA DEL RECEPTOR DP SE ADMINISTRA PARA REDUCIR, PREVENIR O ELIMINAR EL SONROJO QUE, DE OTRO MODO, SE PODRIA PRODUCIR.
GT200400098A 2003-05-15 2004-05-13 Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas. GT200400098A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47066503P 2003-05-15 2003-05-15

Publications (1)

Publication Number Publication Date
GT200400098A true GT200400098A (es) 2005-03-03

Family

ID=33476734

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200400098A GT200400098A (es) 2003-05-15 2004-05-13 Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas.

Country Status (44)

Country Link
US (4) US20040229844A1 (es)
EP (3) EP1624871B1 (es)
JP (2) JP4637833B2 (es)
KR (2) KR100806008B1 (es)
CN (3) CN101559227B (es)
AR (1) AR041089A1 (es)
AU (2) AU2004240597B2 (es)
BR (1) BRPI0410273A (es)
CA (1) CA2525772C (es)
CL (1) CL2004001056A1 (es)
CO (1) CO5630034A2 (es)
CR (2) CR8047A (es)
CY (2) CY1109476T1 (es)
DE (1) DE602004022036D1 (es)
DK (2) DK1624871T3 (es)
DO (1) DOP2004000907A (es)
EA (2) EA009744B1 (es)
EC (1) ECSP056156A (es)
ES (2) ES2328148T3 (es)
GE (2) GEP20084569B (es)
GT (1) GT200400098A (es)
HN (1) HN2004000171A (es)
HR (2) HRP20090424T1 (es)
IL (1) IL171962A (es)
IS (1) IS2708B (es)
JO (1) JO2564B1 (es)
MA (1) MA27835A1 (es)
ME (1) MEP60108A (es)
MX (1) MXPA05012272A (es)
MY (1) MY140639A (es)
NO (1) NO20055957L (es)
NZ (2) NZ572515A (es)
PA (1) PA8603201A1 (es)
PE (1) PE20050552A1 (es)
PL (2) PL2116244T3 (es)
PT (2) PT1624871E (es)
RS (3) RS52731B (es)
SG (1) SG153667A1 (es)
SI (2) SI2116244T1 (es)
TN (1) TNSN05290A1 (es)
TW (2) TWI341199B (es)
UA (1) UA89615C2 (es)
WO (1) WO2004103370A1 (es)
ZA (1) ZA200508288B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395590B1 (en) * 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists
EP1603585A2 (en) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2525497T3 (es) 2004-10-08 2015-10-09 Forward Pharma A/S Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) * 2005-01-19 2012-04-24 The Trustees Of The University Of Pennsylvania Methods for identifying inhibitors of vascular injury
JP2008530250A (ja) * 2005-02-17 2008-08-07 メルク エンド カムパニー インコーポレーテッド アテローム性動脈硬化症、脂質代謝異常及び関連症状の治療方法
AU2006214286A1 (en) * 2005-02-18 2006-08-24 Arena Pharmaceuticals, Inc. Methods and compositions for the treatment of lipid-associated disorders
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP4975739B2 (ja) * 2005-05-17 2012-07-11 シェーリング コーポレイション 脂質異常症の処置のための、ニコチン酸受容体アゴニストとしての複素環
US7750015B2 (en) * 2005-05-17 2010-07-06 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
JP2009507791A (ja) * 2005-08-29 2009-02-26 メルク エンド カムパニー インコーポレーテッド ナイアシン受容体アゴニスト、このような化合物を含有する組成物、および治療方法
JP2009507024A (ja) * 2005-09-01 2009-02-19 アレイ バイオファーマ、インコーポレイテッド Ｒａｆ阻害剤化合物およびその使用方法
WO2007042035A2 (en) * 2005-10-07 2007-04-19 Aditech Pharma Ab Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
AU2006331994A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Combination of an H3 antagonist/inverse agonist and an appetite suppressant
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US7763623B2 (en) * 2006-01-20 2010-07-27 Schering Corporation Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US20090069275A1 (en) * 2006-02-17 2009-03-12 Rocca Jose G Low flush niacin formulation
CA2663434A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
EP2091534A1 (en) * 2006-09-15 2009-08-26 Schering Corporation Azetidinone derivatives and methods of use thereof
WO2008033464A2 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives for the treatment of disorders of the lipid metabolism
WO2008039882A1 (en) * 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US20100260841A1 (en) * 2007-02-08 2010-10-14 Paolini John F Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched laropiprant
CN101559058B (zh) * 2008-04-16 2011-07-20 北京本草天源药物研究院 一种治疗血脂异常的药物组合物
NZ589469A (en) * 2008-05-20 2012-08-31 Cerenis Therapeutics Holding S A Niacin and NSAID combination for reducing niacin-induced flushing
US8507473B2 (en) 2008-09-11 2013-08-13 Arena Pharmaceuticals, Inc. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
WO2010036600A1 (en) * 2008-09-24 2010-04-01 Merck Sharp & Dohme Corp. Pharmaceutical compositions of atorvastatin
WO2010075069A1 (en) 2008-12-16 2010-07-01 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
DK2379063T4 (da) 2009-01-09 2021-05-25 Fwp Ip Aps Farmaceutisk præparat omfattende en eller flere fumarsyreestere i en erosionsmatrix
AU2011227417A1 (en) 2010-03-16 2012-10-11 Aventis Pharmaceuticals Inc. Substituted pyrimidines as prostaglandin D2 receptor antagonists
CA2793324A1 (en) 2010-03-16 2011-09-22 Aventis Pharmaceuticals Inc. A substituted pyrimidine as a prostaglandin d2 receptor antagonist
US20180021302A1 (en) 2015-02-13 2018-01-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3535326A (en) * 1967-03-06 1970-10-20 Sumitomo Chemical Co Certain tetrahydro carboline derivatives
BE787444A (fr) * 1971-08-13 1973-02-12 Hoffmann La Roche Composes polycycliques
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) * 1973-10-01 1977-11-08 American Home Products Corporation Carbazole acetic acid derivatives
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
WO1979000169A1 (en) 1977-09-30 1979-04-05 Rca Corp Television system scheduler
US4342767A (en) 1980-01-23 1982-08-03 Merck & Co., Inc. Hypocholesteremic fermentation products
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5021447A (en) * 1986-01-23 1991-06-04 Merck Frosst Canada, Inc. Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja) 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体
US5190972A (en) * 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU5787996A (en) * 1995-04-19 1996-11-07 Lipoprotein Technologies, Inc. Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
CZ293957B6 (cs) 1995-10-31 2004-08-18 Scheringácorporation @@Azetidinony substituované cukernými zbytkyŹ použitelné jako hypocholesterolemikaŹ farmaceutický prostředek a kit je obsahující
WO1997016424A1 (en) 1995-11-02 1997-05-09 Schering Corporation Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
AU725622B2 (en) 1995-12-22 2000-10-19 Kowa Company, Ltd. Pharmaceutical composition stabilized with a basic agent
US5739321A (en) 1996-05-31 1998-04-14 Schering Corporation 3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5886171A (en) 1996-05-31 1999-03-23 Schering Corporation 3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5756470A (en) 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
ATE451926T1 (de) * 1997-07-31 2010-01-15 Abbott Respiratory Llc Zusammensetzung enthaltend einen hmg-coa- reduktasehemmer und eine nikotinsäureverbindung zur behandlung von hyperlipidämie
HUP0101110A3 (en) * 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en) 1998-02-23 2000-10-17 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en) 1998-10-02 1999-07-06 Schering Corporation Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CA2353981C (en) 1998-12-07 2005-04-26 Schering Corporation Process for the synthesis of azetidinones
EP1354604A1 (en) 1998-12-23 2003-10-22 G.D. Searle LLC. Combinations for cardiovascular indications
CA2367289C (en) 1999-04-05 2008-02-12 Schering Corporation Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(r)-[3(s)-hydroxy-3-(4-fluorophenyl)propyl)]-4(s)-(4-hydroxyphenyl)-2-azetidinone
WO2000063703A1 (en) 1999-04-16 2000-10-26 Schering Corporation Use of azetidinone compounds
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
NZ521192A (en) 2000-03-09 2005-01-28 Ono Pharmaceutical Co Indole derivatives, process for preparation of the same and use thereof
WO2003022814A1 (en) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Indole derivatives
US20010047027A1 (en) * 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
JP2002008186A (ja) * 2000-06-23 2002-01-11 Mitsubishi Heavy Ind Ltd 車種識別装置
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) * 2000-09-13 2007-03-07 三洋電機株式会社 映像信号処理回路
US20040254224A1 (en) 2001-04-11 2004-12-16 Foord Steven Michael Medicaments
EP1395590B1 (en) * 2001-05-23 2006-09-27 Merck Frosst Canada & Co. Dihydropyrrolo¬1,2-a|indole and tetrahydropyrido¬1,2-a|indole derivatives as prostaglandin d2 receptor antagonists
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
CA2479352A1 (en) * 2002-03-19 2003-09-25 Ono Pharmaceutical Co., Ltd. Carboxylic acid compound and a pharmaceutical agent comprising the compound as an active ingredient
PT1513519E (pt) * 2002-06-03 2009-05-06 Novartis Ag Uso de cianopirrolidinas substituídas e preparações de combinações que as contêm para tratar hiperlipidemia e doenças associadas
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) * 2005-07-01 2008-08-06 タキゲン製造株式会社 ステー

Also Published As

Publication number Publication date
WO2004103370A1 (en) 2004-12-02
SG153667A1 (en) 2009-07-29
RS52731B (sr) 2013-08-30
CA2525772A1 (en) 2004-12-02
PL1624871T3 (pl) 2009-12-31
EP2116244B1 (en) 2012-08-08
PL2116244T3 (pl) 2013-01-31
RS20120498A1 (sr) 2013-08-30
CA2525772C (en) 2011-03-15
PT2116244E (pt) 2012-11-02
EA009744B1 (ru) 2008-04-28
EP2116244A1 (en) 2009-11-11
US20090233977A1 (en) 2009-09-17
EP1624871B1 (en) 2009-07-15
GEP20105025B (en) 2010-06-25
PT1624871E (pt) 2009-09-07
EP1624871A1 (en) 2006-02-15
CN101559227A (zh) 2009-10-21
MA27835A1 (fr) 2006-04-03
HK1092722A1 (zh) 2007-02-16
CY1109476T1 (el) 2014-08-13
JP2006526030A (ja) 2006-11-16
KR100806008B1 (ko) 2008-02-26
JP4637833B2 (ja) 2011-02-23
ES2392743T3 (es) 2012-12-13
US20100076002A1 (en) 2010-03-25
RS20120499A1 (sr) 2013-08-30
CN1787819A (zh) 2006-06-14
AU2004240597A1 (en) 2004-12-02
AR041089A1 (es) 2005-05-04
CR9808A (es) 2008-07-29
JO2564B1 (en) 2010-11-03
UA89615C2 (ru) 2010-02-25
TWI341199B (en) 2011-05-01
EA200702674A1 (ru) 2008-04-28
RS20050777A (sr) 2008-04-04
HRP20090424T1 (en) 2009-09-30
KR20060012617A (ko) 2006-02-08
BRPI0410273A (pt) 2006-05-16
CR8047A (es) 2006-07-14
NO20055957L (no) 2006-02-14
PE20050552A1 (es) 2005-08-06
ZA200508288B (en) 2008-08-27
AU2011200986B2 (en) 2012-11-08
NZ572515A (en) 2010-07-30
DOP2004000907A (es) 2004-11-30
US20110118292A1 (en) 2011-05-19
TNSN05290A1 (en) 2007-07-10
ES2328148T3 (es) 2009-11-10
CN100441184C (zh) 2008-12-10
EA200501817A1 (ru) 2006-06-30
DK2116244T3 (da) 2012-11-26
IL171962A0 (en) 2006-04-10
HN2004000171A (es) 2011-07-11
ECSP056156A (es) 2006-04-19
PA8603201A1 (es) 2005-02-04
HRP20120818T1 (hr) 2012-11-30
MXPA05012272A (es) 2006-05-19
TW200503757A (en) 2005-02-01
AU2011200986A1 (en) 2011-03-31
MEP60108A (en) 2011-05-10
CY1113342T1 (el) 2016-06-22
IS8071A (is) 2005-10-13
CN101559227B (zh) 2012-03-21
DE602004022036D1 (de) 2009-08-27
DK1624871T3 (da) 2009-11-16
IS2708B (is) 2011-01-15
NZ543399A (en) 2009-02-28
TWI334354B (en) 2010-12-11
CO5630034A2 (es) 2006-04-28
IL171962A (en) 2012-06-28
GEP20084569B (en) 2008-12-25
SI1624871T1 (sl) 2009-12-31
TW200803844A (en) 2008-01-16
CL2004001056A1 (es) 2005-03-28
EP2286816A1 (en) 2011-02-23
SI2116244T1 (sl) 2012-12-31
CN102526735A (zh) 2012-07-04
AU2004240597B2 (en) 2011-01-06
KR100960749B1 (ko) 2010-06-01
MY140639A (en) 2010-01-15
KR20080003470A (ko) 2008-01-07
EA011895B1 (ru) 2009-06-30
JP2010077151A (ja) 2010-04-08
US20040229844A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
GT200400098A (es) Metodo de tratamiento de aterosclerosis, dislipidemias y condiciones relacionadas y composiciones farmaceuticas.
TW200733971A (en) CGRP peptide antagonists and conjugates
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
NZ608673A (en) Therapeutic use of a tlr agonist and combination therapy
MX2019011530A (es) Saxitoxinas 11,13-modificadas para el tratamiento del dolor.
NO20073831L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MX2012004848A (es) Compuestos heterociclicos triciclicos.
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
TNSN07341A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
EP2328414A4 (en) SUBSTITUTED TRIAZOLO-PYRIDAZINE DERIVATIVES
BRPI0809931B8 (pt) antagonistas do receptor do hormônio liberador de gonadotrofina e métodos relacionados com o mesmo
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
MX2009005798A (es) Recuperacion de apoplejia.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
AR044675A1 (es) Metodo para el tratamiento de la esquizofrenia en un paciente con sobrepeso
MX2012015102A (es) Agentes terapeuticos 976.
MX2008011842A (es) Procedimientos y composiciones para el tratamiento de insuficiencia cardiaca diastolica.
WO2019104062A8 (en) Polymorphs and uses thereof
TW200700084A (en) Combination of sodium channel blockers and their derivatives with opioid antagonists
RU2007120403A (ru) Способ локальной терапии аутоиммунного артрита
CR20210059A (es) Composiciones farmacéuticas y métodos para el tratamientos de la trombosis y administración a través de dispositivos médicos